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Abstract
SPL7013 is the sodium salt of a sulfonated dendrimer that has potent antiviral properties. VivaGel®,
a topical gel containing 3% w/w SPL7013, has been shown to be safe and well-tolerated in human
clinical studies. BufferGel® is a Carbopol®-based acidic buffering gel that enhances the natural
protective action of the vagina to produce a broad-spectrum microbicidal environment. The positive
attributes of both gels were combined into a combination vaginal microbicidal gel having dual
mechanisms of action. A 3% w/w SPL7013 combination gel, pH 3.7, was developed and fully
characterized, and was shown to have more than 2-fold greater acidic buffering capacity than
BufferGel. Ultracentrifugation experiments demonstrated that SPL7013 was not sequestered or
entropically trapped in the viscous gel, thereby confirming, along with viral challenge studies, that
SPL7013 has sufficient mobility in the viscous gel to exert antiviral properties.
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INTRODUCTION
The incidence of HIV infection continues to grow rapidly, with the most recent data from the
United Nations showing that 42 million people worldwide are HIV positive (Tanne, 2006;
Zarocostas, 2005). Of particular concern is the high percentage of women who have become
infected with HIV. In those parts of the world where the primary means of infection is through
heterosexual contact, women comprise up to 60% of the total infected population. An additional
concern with the increasing number of HIV infected women is the increased rate of
transmission of HIV to the newborn. Thus, there is an urgent need for strategies to prevent HIV
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infection during sexual contact. One strategy is the use of microbicides, which are chemical
entities that can prevent or reduce transmission of sexually transmitted infections (STIs) when
applied to the vagina or rectum (Ndesendo 2008). Microbicidal candidates have included,
among others, 1) macromolecular polyanions such as PRO 2000 (naphthalene 2-sulphonate
polymer), cellulose sulfate, dextran sulfate, and carrageenan, (Cummins 2007; Maguire
2001; Neurath 2002; Turpin, 2002) or 2) acidic buffering gels, which exert their activity by
inducing or maintaining low vaginal pH, wherein viruses such as HIV and HSV, cellular
vectors such as HIV-infected cells, and pathogenic bacteria are inactivated (Olmsted 2005;
Patton 2004; Williams 2007; Zeitlin 2001)
Dendrimers are a relatively new class of macromolecule characterized by highly branched,
three-dimensional architectures that offer an alternative to polyanionic microbicidal polymers
(McCarthy 2005). The controlled synthesis of dendrimers allows the assembly of highly
defined structures that radiate out in generations from a central initiator core. Several anionic
dendrimers have been synthesized and tested in-vitro and in-vivo for their anti-viral properties.
In fact, selected anionic dendrimers are potent inhibitors of a range of STI’s, including HIV-1,
HSV-1, and HSV-2. One such polyanionic dendrimer being developed by Starpharma Pty. Ltd,
SPL7013 (16,581 Da), is built up from a divalent core, the benzhydrylamine amide of L-lysine
(Figure 1). Successive additions of four L-lysine layers leads to a dendrimer with 32 amine
groups on the surface; 16 α-amines and 16 ε-amines from the outer L-lysine layer. The final
step in the synthesis involves the last amide-bond-forming reaction to attach 32 sodium (1-
naphthyleneyl-3,6-disulphonic acid)-oxyacetamido groups to the surface via amide linkers.
The EC50 of SPL7013 against HIV-1 (Strain IIIB) was <1 µg/ml (Bernstein 2003; Gong
2005). In addition, SPL7013 was found to be highly active against CCR5- and CXCR4-tropic
HIV-1 infection (Lackman-Smith 2008). A 5% w/w SPL7013 vaginal gel was found to
completely prevent vaginal transmission of SHIV89.6P in female pigtailed macaques (Jiang
2005). In June 2003, the SPL7013 gel (termed VivaGel) was the first submission to the US
FDA for a dendrimer-based drug. Initial human trials have shown VivaGel to be safe and well-
tolerated (Rupp 2007), and additional clinical studies are on-going. Roth et al. recently showed
that a SPL7013 gel significantly reduced the amount of HIV1 bound to epithelial cells in-
vitro versus placebo gel (Roth 2007). In addition, Abner et al. showed that SPL7013 gel
significantly reduced HIV-1 infection in human colorectal explant tissue versus placebo (Abner
2005). Rupp provides an excellent review of the HIV and HSV antiviral activity of SPL7013
and SPL7013-containing gels in in-vitro and animal models (Rupp 2007).
BufferGel is a broad-spectrum microbicide/spermicide gel being developed by ReProtect Inc.
that enhances the protective action of vaginal acidity (Ballagh 2008; Patton 2004; Van De
Wijgert 2001; Williams 2007). BufferGel is a non-toxic lubricant gel formulated at pH 3.8, the
pH of the healthy vagina. BufferGel is made with a strongly buffering polymer, Carbopol 974P,
that releases protons to acidify the ejaculate, thereby enhancing the protective acidity of the
vagina and complementing the acidifying action of lactobacilli, the vaginal flora that create
the protective acidity of the vagina (Olmsted 2000; Olmsted 2005). Human clinical trials have
shown BufferGel to be safe, acceptable, and less inflammatory and tissue-destructive than
detergent-based spermicides (Cone 2006; Mayer 2001; Patton 2004; Van De Wijgert 2001),
and it is currently being investigated in Phase 3 clinical trials.
The overall goal of the present studies was to combine SPL7013 dendrimer in a Carbopol-
based acidic buffering gel to create a microbicidal gel having dual mechanisms of action.
Various combination vaginal gels were prepared and tested for pH, osmolality, buffering
capacity, and viscosity. The effect of temperature, pH, and SPL7013 concentration on gel
viscosity was also determined. Since SPL7013 dendrimer is a polyanionic macromolecule,
there was some concern that its diffusion would be constrained in a viscous Carbopol-based
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gel thereby reducing its antiviral activity. Thus, an ultracentrifugation method was developed
to ascertain the tendency of SPL7013 to be sequestered or trapped in the viscous gel.
MATERIALS AND METHODS
Materials
Carbopol 974P NF and Carbopol 971P NF were obtained from Lubrizol Corporation (Wickliff,
OH). Lactic acid, USP, methyl paraben NF, propyl paraben NF, Edetate Disodium USP
(ethylenediaminetetraacetic acid disodium; EDTA disodium), glacial acetic acid, potassium
hydroxide NF, sodium chloride (0.9% w/v), and sodium hydroxide NF were purchased from
Spectrum Quality Products, Inc. (New Brunswick, NJ). SPL7013 dendrimer (lot #08-036-026-
02) was provided by Starpharma Pty. Ltd. (Melbourne, Australia). The SPL7013 synthetic
process is monitored by HPLC and LC/MS in-process controls and delivers SPL7013 as a
single molecular entity as determined by HPLC, capillary electrophoresis (CE), and
electrospray mass spectral analysis.
Gel Preparation
The gels were prepared using a modification of a previously published method (Bernstein
2003) using a Caframo Ultrahigh-Torque Stirrer Model BDC1850 (Wiarton, Ontario, Canada)
with a 5.1 cm stainless steel propeller blade. A general formula and method is provided for
preparing 200 g batches based on Carbopol 974P. Specifically, MilliQ water (167 g) was added
to the stirring vessel with stirring at 800 rpm. Next, 300 mg EDTA disodium USP was added
and allowed to dissolve (2 min). Next, 8.68 g Carbopol 974P was then added slowly over 15–
20 min while stirring at 1000 rpm to allow for homogeneous hydration of the polymer. Next,
360 mg methyl paraben and 40 mg propyl paraben were added and allowed to dissolve over 5
min. Lactic acid (1000 µL) and acetic acid (166 µL) were then added and allowed to mix for
2 min. SPL7013 dendrimer (6.795 g) was then added and allowed to completely dissolve. An
additional 3.72 g of Carbopol 974P was then added while stirring at 1200 rpm over 15–20
minutes. Finally, the pH was adjusted to the target pH of 3.7–3.8 using 2N KOH (~7.3 mL)
and the batch was then q.s. to 200 g with MilliQ water. Additionally, in order to test the effect
of final gel pH on viscosity, gels were made having final pHs of 3.4, 3.6, 3.8, 4.0, and 4.2.
Finally, to determine the effect of SPL7013 dendrimer on gel viscosity, four gels were made
having a final pH 3.7–3.8 with 6.2% w/w Carbopol 974P and lactic and acetic acids and
containing final SPL7013 concentrations of 3%, 4%, 5%, and 6%.
Gel Characterization Methods
The viscosity of the gels was determined using a Brookfield Cone and Plate Rheometer RVDV-
III+ (Brookfield Engineering; Middleborro, MA) at 25°C at 5 min at an RPM of 1.7 using
Spindle CPE-52. For some gel samples, the viscosity was tested at various temperatures (in
the range of 4–37°C) to ascertain the effect of temperature on gel viscosity. For these
measurements, the rheometer was pre-equilibrated to the desired temperature using a
circulating water bath. Osmolality was determined using a FISKE 110 Freezing-Point
Depression Osmometer. The pH of the gels was determined using an Orion pH Meter Model
520A. The buffer capacity was determined by measuring the number of mEq of 0.5N NaOH
titrametric standard needed to bring 2.5 g of the formulation from its starting pH of
approximately 3.8 to a final pH of 5.0. Specifically, approximately 2.5 g of the sample was
deposed in a beaker. The sample was mixed with 20.0 mL of 0.9% NaCl solution using a stir
bar for 5 min at a temperature of 23–25°C. The homogeneously mixed sample was then titrated
with standardized 0.5 N NaOH solution until the pH of the mixture was 5.0. The volume of
the NaOH needed to raise the pH to 5.0 was recorded and the buffer capacity of the sample
was calculated using the following equation:
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SPL7013 Dendrimer Sequestration Experiments
Experiments were conducted in order to determine the relative extent of sequestration of
SPL7013 in centrifuged prototype combination vaginal gels. One (1) gram samples of the
indicated 3% w/w gels were ultracentrifuged using a Beckman TL-100 Ultracentrifuge with
T100.3 rotor at 25° C at 50,000 rpm for 30 min, along with 1 g samples of a 3% w/w SPL7013
solution, in order to assess settling and sedimentation, if any, of the SPL7013 in solution, as
well as to serve as a control for assaying SPL7013 concentrations. After centrifugation for 30
min, a 100 µL aliquot part of the supernatant was carefully aspirated from each sample and
diluted in deionized water to a fixed final volume of 20 mL. In order to determine the
concentration of SPL7013 retained in the dense gel layers, the remaining supernatant was
carefully decanted, and a 100 mg sample of the gel layer was removed with a spatula, placed
in a flask, and similarly diluted. Standard curves of each gel and the control solution were
prepared by assaying the UV absorbance (332 nm) of serial dilutions of the 3%w/w SPL7013
control solution and the two 3%w/w starting control gels. UV spectroscopy at 332 nm was
selected as the analytical method, since the Carbopol polymers showed no absorbance at this
wavelength, obviating the need for chromatographic separation of components, while SPL7013
displayed an absorption peak at 332 nm. No interference from gel components was noted at
332 nm using this assay, as all three curves were nearly superimposable, with nearly identical
linearity and linear equations (data not shown).
RESULTS AND DISCUSSION
Background and Target Composition for Prototype Combination Vaginal Gels
The compositions of BufferGel and VivaGel are shown in Table 1. All excipients for both
BufferGel and VivaGel are generally regarded as safe (GRAS) when used in the amounts listed
for vaginal administration. It should be noted that the concentration of BufferGel excipients is
not publicly disclosed. Both gels are currently under human clinical testing for safety and
efficacy. The gels are aqueous Carbopol-based gels with the notable difference that BufferGel
contains Carbopol 974P while VivaGel contains Carbopol 971P. Carbopol 974P and Carbopol
971P have some important similarities and differences, as shown in Figure 2. Whereas
Carbopol 974P is a highly crosslinked, high viscosity polymer with a consistency and flow
like mayonnaise, Carbopol 971P is a lightly crosslinked low viscosity polymer with a
consistency and flow like honey. Carbopol 971P is both more pH- and salt-tolerant, meaning
that the viscosity of Carbopol 971P-containing gels is less affected by changes in pH and salt
concentration. This fact was considered in the initial development of VivaGel, since the
addition of 3% w/w SPL7013 resulted in a sodium concentration of 115 mM, which
significantly affected gel viscosity. Specifically, the addition of 3% w/w SPL7013 to an
otherwise viscous Carbopol-based gel made with 3–5% w/w Carbopol in the pH range of pH
3–3.8 caused a substantial if not complete loss of viscosity for both Carbopol 971P and
Carbopol 974P-based gels. Interestingly, magnesium sulfate is added to BufferGel to reduce
the viscosity of the formulation to that acceptable for vaginal administration and product use.
Carbopol-based gels are known to be comprised of swollen microgel particles having both a
macroviscosity and microviscosity. As shown in Figure 2, highly cross-linked polymers such
as Carbopol 974P have more rigid gel microparticles (globules) when hydrated, while lightly
cross-linked polymers such as Carbopol 971P are extended and flexible, thereby creating a
more cage-like structure. As a consequence, the release rate of drugs from Carbopol 974P-
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based gels is usually greater than those from Carbopol 971P-based gels. For example, MacLean
et al., using x-ray fluorescence, showed that the release rate of iodine-labeled bovine serum
albumin from subcutaneously injected Carbopol-based gels was significantly greater for
highly-crosslinked Carbopol 940 gels as compared to less crosslinked Carbopol-based gels
(MacLean-McDavitt 2003).
As described in the Introduction, SPL7013 is a high molecular weight dendrimer, with a multi-
layered lysine backbone and a polyvalent naphthalene sulphonic acid surface. The size of the
dendrimer and the large number of degrees of freedom in the scaffold result in a highly mobile
structure comprising both hydrophilic (i.e. lysine moieties, and charged sulphonic acid groups)
and hydrophobic (i.e. naphthyl rings) regions, in addition to the association of 64 Na+ ions per
molecule. Both Carbopol 971P and 974P are formed by crosslinking acrylic acid with allyl
ethers of pentaerythritol, giving a saturated structure rich in ether, carbonyl and hydroxyl
moieties. Carbopol might form intermolecular interactions with SPL7013 (via hydrogen
bonding of dendrimer NH groups with Carbopol carbonyl groups, or dendrimer carbonyls and
Carbopol hydroxyls). Additionally, encapsulation of SPL7013 in the polymer matrix might
arise due to the size, shape and flexibility of the compound in solution versus the matrix of
polymer chains formed by the Carbopol. Moreover, the differing extent of crosslinking between
Carbopol 971P and 974P could result in varied sequestration behavior of SPL7013 in these
two gelling agents.
To achieve a prototype combination vaginal gel product with desirable product features, a
series of 974P and 971P gels containing SPL7013 were produced and evaluated both
qualitatively and quantitatively. Although each of the Carbopol types provide some theoretical
advantages, Carbopol 974P-based gels were pursued for the combination vaginal gel since
placebo Carbopol 971P-based gels tended to be more ‘sticky’ to the touch with a consistency
like ‘honey’.
The assessment of the prototype gels lubricity (or conversely, stickiness) is primarily
determined by touch. However, as this evaluation is conducted external to the body it is
acknowledge that internal application of the gel (into a warmer, higher humidity environment)
may result in slightly different feel. In order to simplify the prototype formulations, it was
elected to omit any emollient (e.g. the 1% w/w propylene glycol or glycerin that are included
in VivaGel) unless required to enhance the physical feel. If the prototype formulations were
judged to need an emollient, then low levels (<10% w/w) would be included to avoid any
potential mucosal irritation that has been observed at high concentrations with such excipients
and which is caused by the high osmolality of the ensuing gels (Adriaens 2008). In addition to
the in-vivo (slug) evaluation of toxicity related to high glycerol content, the use of a
hyperosmolar gel formulation in a Phase I clinical trial resulted in unacceptable adverse events
(i.e. abnormal transudation of physiologic fluid across the cervico-vaginal mucosae) due to the
high glycerin content (Lacy 2008).
Both lactic and acetic acid were included in the combination vaginal gel product (Prototype
1), as these cell-permeant species, naturally occurring in the vagina, have been shown to
inactivate both viral and bacterial pathogens (Dimitonova 2007). Methyl and propyl parabens
were chosen as the preservative in the prototype combination vaginal gels. The levels of the
parabens are standard in topical products for providing antimicrobial properties, but further
confirmed by antimicrobial effectiveness testing (AET) on the prototype gel formulations (data
not shown).
Prototype Combination Vaginal Gels
Gel composition and characterization—The composition and characterization of
combination vaginal gel prototypes is shown in Table 2. The final prototypes with lactic and
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acetic acids (termed “Prototype 1”) and without lactic and acetic acid (termed “Prototype 2”)
were prepared using 6.2% w/w Carbopol 974P at a pH of 3.7. This relatively high Carbopol
content was required in order to maintain sufficient viscosity of the vaginal gel, since the
formulation of 3% w/w SPL7013 introduced a final sodium concentration of ~115 mM, which
substantially reduced the gel viscosity at the relatively low pH of the prototype formulations.
The reduction of viscosity of Carbopol-based gels by sodium is well known. Moreover, it was
independently confirmed that the addition of 57.5 mM NaCl to a pH of 3.7, and concentration
of 3.8% w/w Carbopol 974P gel without SPL7013 reduced the viscosity to nearly that of water.
In Figure 3, the effect of percent Carbopol 974P on the resulting viscosity of 3% w/w SPL7013
gels is plotted. There was a linear [R2 = 0.9796] relationship between Carbopol content and
resulting gel viscosity. Interestingly, it was very difficult to produce a gel containing 6.2% w/
w Carbopol 974P in the absence of SPL7013 (and its associated viscosity-reducing sodium
ions), since the extremely high viscosity hindered mixing. These findings helped in defining
a suitable manufacturing process for the gel wherein roughly half of the Carbopol is added first
to make a gel base, and the remainder is added after the SPL7013 dendrimer is added.
Coincidentally, the necessity of increasing the Carbopol 974P content in the prototype
combination vaginal gels due to the inclusion of SPL7013 also resulted in gels having
significantly increased acidic buffering capacity as compared to that of BufferGel. Whereas
BufferGel and VivaGel had acidic buffering capacity of 0.15 mEq/g and 0.12 mEq/g,
respectively, Prototype 1 and Prototype 2 had acidic buffering capacities more than 2-fold
greater of 0.32 mEq/g and 0.29 mEq/g, respectively. The addition of physiological levels of
lactic (0.6% w/w; 67 mM) and acetic acid (0.087% w/w; 15 mM) in Prototype 1 resulted in
about a 90% increase in the osmolality of Prototype 1 versus Prototype 2 with an increase in
the acidic buffering capacity of 10%. In comparison, the inclusion of 1% w/w propylene glycol
and 1% w/w glycerin in the VivaGel formulation contributed to its increased osmolality of 380
mOsm/kg H2O. With reference to the above discussion on hyperosmolar formulations inducing
mucosal toxicity (Adriaens 2008;Lacy 2008), it should be noted that adverse toxicological
behavior is observed with osmolality values greater than 2000 mOsm/kg H2O, i.e. substantially
greater than those measured for formulations described here.
Gel Characterization
Effect of pH, temperature, and Percent SPL7013 on Gel Viscosity—In order to
address concerns over the effects of pH and temperature on the viscosity of the combination
vaginal gel prototypes, gels containing 5.5% w/w Carbopol 974P and SPL7013 at various pHs
were prepared. As shown in Figure 4A, there was a relatively small increase in viscosity in
gels having a pH at or below pH 3.8. However, above pH 3.8, there was an exponential increase
in viscosity which is consistent with what is known about Carbopol-based gels alone in aqueous
vehicles. These results suggested that target pH of the gel could be lowered to pH 3.7 and allow
for even greater buffering capacity. The effect of temperature on the viscosity of a 3% w/w
SPL7013 Prototype 1 (pH 3.7) was also investigated. As shown in Figure 4B, a plot of viscosity
versus temperature demonstrated that the viscosity of Prototype 1 varied only modestly across
this relatively broad temperature range. The information from these studies should prove
extremely useful for large scale manufacturing of the Prototype 1 and subsequent storage.
Lastly, the effect of SPL7013 concentration on Prototype 1 gel viscosity in plotted in Figure
4C. As expected, as the SPL7013 concentration increased, the resulting gel viscosity decreased
in an almost linear manner. It was concluded that a maximum of 4% w/w SPL7013 could be
formulated in the Prototype 1 gel allowing the vaginal gel formulation to have sufficient
viscosity for administration (i.e. >5,000 cP using this method).
Ultracentrifugation of SPL7013 Gels—The phenomenon of ‘entropic trapping’ of
macromolecules in the void space of polymer hydrogels has previously been described (Liu
1999). Entropic trapping is influenced by molecular size dependent diffusion of the
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macromolecule. The mean (z-average) diameter of SPL7013 as determined by dynamic light
scattering measurements (at 1 mg/ml in 10−2M NaCl) (Prestidge 2005) is 5 nm. This correlates
well to the Stokes diameter of approximately 3–4 nm which may be calculated based on its
molecular weight of 16,581 Da. It was therefore hypothesized that Carbopol 974P in the viscous
gel might bind or trap SPL7013 by either entropic trapping or hydrogen bonding, thereby
leaving some SPL7013 less available for interaction with HIV, HSV, or semen. This would be
an obvious concern for a vaginal microbicidal gel product containing an anti-viral compound
that required the compound to physically interact with the virus in order to exert activity.
Importantly, previous studies have suggested that the rate of diffusion of molecules decreases
with increasing size (Flemstrom 1999). For example, Flemstrom et al. showed that the mucus
gel layer in the duodenum significantly restricts migration of macromolecules to the duodenal
surface. However, Olmsted et al. later showed, using improved analytical methods and
employing fluorescent recovery after photobleaching (FRAP) and fluorescent imaging, that
large proteins (15–650 kDa) and even small viruses such as the human papilloma virus (55
nm) and Norwalk virus (38 nm) could diffuse as rapidly in mucus as in saline (Olmsted
2001). It was demonstrated that the mesh spacing between mucin fibers (20–200 nm) was large
enough to allow these macromolecules to diffuse unconstrained. Still, the diffusion of larger
proteins as well as that of the herpes simplex virus (180 nm) were hindered by the viscous
mucin.
Analytical ultracentrifugation is a common and powerful method employed to quantify the size
and shape of macromolecules and their interactions (Howlett 2006). This method has many
different applications, including the study of molecular associations and reactions under
equilibrium conditions, as well as to ascertain macromolecule size and shape. For example,
Howlett et al. review the uses of ultracentrifugation to study protein association and assembly
(Howlett 2006). In addition, Joralemon et al. used analytical ultracentrifugation to study the
sedimentation equilibrium of formed nanostructures resulting from polymeric micelles
crosslinked with divergently synthesized dendrimers (Joralemon 2005).
In the present studies, we intended to adapt ultracentrifugation to determine if SPL7013
dendrimer was sequestered in Carbopol 974P and Carbopol 971P-based aqueous gels. As
shown in Figure 5A, tubes containing SPL7013 or SPL7013-containing gels were subjected
to ultracentrifugation for 30 min at 50,000 rpm to phase separate the gels into a water-rich band
(“water-band”) and gel-rich band (“gel-rich band”). Sequestration of SPL7013 by Carbopol
974P would result in a lower than theoretical SPL7013 concentration (e.g., 3% w/w) in the
water-band as shown in Figure 5C. In contrast, concentrations of SPL7013 in the water-band
that were close to 3% w/w (as indicated by Figure 5B) would suggest no discernable binding
or trapping of SPL7013 by Carbopol 974P.
The results showed that ultracentrifugation of an aqueous SPL7013 solution (i.e. absent of any
Carbopol or other excipients) resulted in no significant sedimentation of SPL7013 under the
conditions used for ultracentrifugation (Table 3). The upper layer of a centrifuged SPL7013
solution contained 99.0% ± 0.03% (n=6) of the theoretical SPL7013 concentration.
Ultracentrifugation of both Prototype Vaginal Gels resulted in the formation of distinct watery
supernatants and dense gel-rich bands. Qualitative examination revealed that the water-band
comprised approximately 20% of the volume of the entire gel sample. The aqueous supernatant
was sampled once per vial in order to avoid puncturing or disturbing the gel band. The total
water band volume was not measured, since droplets stuck irregularly to the inside of the vial
and to the pipette tips. Thus, a complete mass balance of SPL7013 in the water and the gel
bands was not performed. As summarized in Table 3, SPL7013 was not sequestered in the
Carbopol-rich band after ultracentrifugation of both the Prototype 1 and Prototype 2 gels.
Instead, the SPL7013 readily diffused from the gel region and concentrated in the watery
supernatant. The concentration of SPL7013 in the water band after ultracentrifugation was
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approximately 50% higher than that in the starting prototype combination vaginal gels, and
significantly lower in the remaining compressed gel bands.
Interestingly, VivaGel (10,183 cP) and a neutral 2.7% w/w hydroxyethyl cellulose (HEC)
placebo gel (otherwise known as the “Universal” placebo, which is commonly used in topical
microbicide development as a comparator formulation) (Tien 2005) could not form discernible
water and gel-rich layers when ultracentrifuged, even after 100,000 rpm for 45 min. Further
examination revealed that viscosity and pH most influenced the ability of the gel to form bands
after ultracentrifugation. For example, VivaGel could be compressed into a water band and a
gel layer if it was acidified with HCl, or if sodium chloride was added into the gel to yield gels
having viscosities between 3,000–4,000 cP. Specifically, when 25 mg 6N HCl or 50 mg 5M
NaCl was added to 1 g VivaGel, ultracentrifugation at 50,000 rpm for 30 min led to banding
and the SPL7013 concentration in the water-band was essentially equivalent to that in the initial
VivaGel formulation. Interestingly, ultracentrifugation did not lead to banding when only 25
mg 5M NaCl was added to 1 g VivaGel. This gel had a viscosity of 6,598 cP, which was actually
lower than the value measured for either of the prototype combination vaginal gels. However,
the pH of this modified VivaGel sample was 4.21, which was still a half pH unit higher than
that of the prototype combination vaginal gels. Thus, the influence of lower pH on reduced
Carbopol ionization and subsequent reduced electrostatic repulsion in promoting gel
compression and SPL7013 diffusion may be particularly important at moderate viscosity
levels. In cases of relatively higher pH, where the Carbopol residues would tend to be
deprotonated and anionic, such as with the prototype combination vaginal gels or the high salt
mixtures, electrostatic repulsion between polymer and SPL7013 may contribute to higher
SPL7013 diffusion and subsequent SPL7013 concentration in the water bands.
In summary, novel combination vaginal gel formulations have been successfully developed
which aimed to combine design and formulation criteria from two leading topical microbicides
currently in human clinical trials. Both prototype gel formulations have been fully
characterized, and demonstrated to have potential utility as topical vaginal microbicide
products. Finally, ultracentrifugation studies have shown that the anti-viral macromolecule
SPL7013 dendrimer is not entropically trapped in Carbopol-based gels and would in turn be
available to physically interact with virus.
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Structure of SPL7013 dendrimer (MW 16,581 Da). Successive additions of four L-lysine layers
to the divalent core of benzhydrylamine amide of L-lysine leads to a final dendrimer molecule
having 32 amide-linked 1-naphthyleneyl-3,6-disulphonic acid)-oxyacetamido groups on the
surface.
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Structure and physical/chemical properties of Carbopol 974P and Carbopol 971P. Both
polymers are Generally Regarded as Safe (GRAS) and strongly mucoadhesive at lower pH due
to H-bonding of the repeating carboxylic moiety (pKa 6 ± 0.5). In addition, aqueous-based gels
made of each polymer are non-Newtonian fluids. Differences between the two polymers are
listed adjacent to their structures.
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The effect of Carbopol 974P concentration on the resulting viscosity (cP) of Prototype 1
Combination Vaginal Gel made with 3% w/w SPL7013 dendrimer.
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The influence of pH (A), temperature (B) and % SPL7013 dendrimer concentration (C) on the
resulting viscosity of Prototype 1 Combination Vaginal Gel. Y-axis for A-C is Viscosity (cP).
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Schematic depicting the physical disposition of SPL7013 dendrimer in Prototype Combination
Vaginal Gels before ultracentrifugation (A), and after ultracentrifugation (B,C).
Ultracentrifugation of the viscous Carbopol-based gel produces a water-rich band (“Water
Band”) on top and a gel-rich band (“Gel Band”) on the bottom of the tube. B shows a water
band with equal concentration of SPL7013 in the Water Band and the Gel Band as would be
expected in the absence of sequestration. C shows a water band with reduced SPL7013
concentration as would be expected if SPL7013 dendrimer were sequestered by the Carbopol-
based gel.
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Table 1
Compositions of BufferGel and VivaGel, and Target Composition for Novel Prototype Combination Vaginal Gels
(Prototypes 1 and 2) Containing SPL7013 Dendrimer
Ingredient
(all values in % w/w)






Carbopol 974P 5.0% Carbopol 971P Carbopol 974P or 971P
pH adjustment Dibasic potassium
phosphate
9% 2N Sodium hydroxide KOH
Preservative Sorbic acid 0.18% methyl paraben and
0.02% propyl paraben







Antioxidant EDTA disodium 0.1% EDTA disodium 0.15% EDTA disodium
Emollient None 1.0% propylene glycol and
1.0% glycerin
None
Viscosity reducer Magnesium sulfate None Not needed due to Na
from Na SPL7013
Inactivation of bacterial
pathogens (GC and BV)
None None Lactic and acetic acids
SPL7013 Dendrimer (active) None 3% 3%
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Table 2







Purified Water q.s. to 100% q.s. to 100%
Methyl Paraben NF 0.18 0.18
Propyl Paraben NF 0.02 0.02
EDTA Disodium USP 0.15 0.15
Carbopol 974P NF 6.2 6.2
Lactic Acid USP 0.6 None
Acetic Acid USP 0.087 None
2N KOH NF q.s. to pH 3.7 q.s. to pH 3.7
SPL7013 Dendrimer 3.0 3.0
Characterization (n = 3.5 batches)
pH 3.7 ± 0.08 3.7 ± 0.03
Viscosity 9484 ± 1344 cP 8245 ± 1693 cP
Buffering Capacity 0.31 ± 0.02 mEq/g 0.28 ± 0.01 mEq/g
Osmolality 202 ± 13 mOsm/kg 102 ± 4 mOsm/kg
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Table 3
Concentration of SPL7013 Dendrimer in Water-Band and Gel-Band after Ultracentrifugation of 3% w/w Prototype 1
and Prototype 2 Vaginal Gels at 50,000 rpm for 30 min
SPL7013 Concentration (% w/w) (n=6)
Material Water-Band Gel-Band
SPL7013
  Aqueous solution, untreated control 3.00 ± 0.03 N/A
  Aqueous solution, ultracentrifuged 2.97± 0.01 N/A
Prototype 1 Vaginal Gel
  Control, untreated 3.03 ± 0.01 3.03 ± 0.01
  Ultracentrifuged 4.54 ± 0.07 2.67 ± 0.06
Prototype 2 Vaginal Gel
  Control, untreated 3.00 ± 0.02 3.00 ± 0.02
  Ultracentrifuged 4.46 ± 0.03 2.49 ± 0.01
Viscosity (cP) pH
VivaGel
  Ultracentifuged 10,183 4.80 No Band 3.00 ± 0.05
  Ultracentrifuged
    after diluting 10% with water 8,830 4.47 No Band 2.74 ± 0.11
    after diluting 5% with water 9,525 4.37 No Band 2.87 ± 0.06
    after diluting 2.5% with water 9,872 4.34 No Band 2.91 ± 0.04
    after diluting 10% with 6N HCl 695 0.66 2.93 ± 0.10 3.56 ± 0.26
    after diluting 5% with 6N HCl 2,009 1.22 2.90 ± 0.08 3.48 ± 0.11
    after diluting 2.5% with water 3,188 1.96 2.84 ± 0.07 3.29 ± 0.12
    after diluting 10% with 5M NaCl 2,914 4.27 3.67 ± 0.08 2.46 ± 0.16
    after diluting 5% with 5M NaCl 3,237 4.23 3.50 ± 0.09 2.62 ± 0.06
    after diluting 2.5% with 5M NaCl 6,598 4.21 No Band 2.97 ± 0.11
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